| scholarly article | Q13442814 |
| P2093 | author name string | Aliaa M Kamal | |
| Suzan M Abuel-Maaty | |||
| Ehab M Gedawy | |||
| Aml E-S Mghwary | |||
| P2860 | cites work | Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors. | Q54236416 |
| New frontiers in kinases: second generation inhibitors | Q54372308 | ||
| Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. | Q55474987 | ||
| Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2 | Q79764476 | ||
| Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer | Q81077408 | ||
| Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers | Q89476190 | ||
| Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells | Q24324117 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors | Q27673353 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition | Q28238040 | ||
| Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer | Q28728593 | ||
| Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells. | Q33589345 | ||
| Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer | Q33710562 | ||
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. | Q34166741 | ||
| The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. | Q36765297 | ||
| New developments in multitargeted therapy for patients with solid tumours | Q36993523 | ||
| EGFR Signals Downregulate Tumor Suppressors miR-143 and miR-145 in Western Diet–Promoted Murine Colon Cancer: Role of G1 Regulators | Q37285463 | ||
| Role of epidermal growth factor receptor in breast cancer | Q37320346 | ||
| Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. | Q39057226 | ||
| Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives | Q39179828 | ||
| Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. | Q39415127 | ||
| Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors | Q39530608 | ||
| Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer. | Q39728936 | ||
| ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. | Q39742390 | ||
| Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. | Q39954175 | ||
| Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells | Q39987883 | ||
| Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects | Q40199390 | ||
| Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. | Q40200943 | ||
| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. | Q40657525 | ||
| Blood vessel formation: what is its molecular basis? | Q41288467 | ||
| Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors | Q42876796 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials | Q47128966 | ||
| Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity | Q49798021 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug discovery | Q1418791 |
| vandetanib | Q7914515 | ||
| P304 | page(s) | 838-852 | |
| P577 | publication date | 2019-12-01 | |
| P1433 | published in | Journal of Enzyme Inhibition and Medicinal Chemistry | Q15708877 |
| P1476 | title | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile | |
| P478 | volume | 34 |
| Q89623173 | Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors | cites work | P2860 |
Search more.